Loading
Illumina, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 Feb 2026.
Illumina, Inc.: what insiders have been doing
Illumina, Inc., classified in the Healthcare & Pharma sector, is a listed company based in San Diego, United States, founded in 1998. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 131 filings signed by 19 insiders.
The record shows 2 purchases on the open market worth €73k, made by 1 insider, against 75 sales worth €376.4M by 4 insiders. The totals exclude 1 filing filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 senior executive among the declarants. One trade stands out by size: a sale of €28.7M from Meister Keith A., disclosed on 6 August 2026, or 0.080% of market capitalisation.
The last purchase on record was published on 11 February 2026, which is 249 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 131 filings in twelve months, the company is more active than the median of 19 filings across the 5,814 companies we follow on the same exchange. Our records for Illumina, Inc. go back to 2016, with 5 purchases and 138 sales on the open market in total. The 10-K for the year ended 28 December 2025 shows 4.34 bn USD of revenue and 850.0 m USD of net income.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
427
Thresholds
n/a
Buy Volume
€1M
5 ops. · all time
Sell Volume
€386M
138 ops. · all time
Who traded when
BuySaleKeith A. Meister67 sales
Davies Scott M5 sales
Ericksen Scott D2 sales
Gottlieb Scott2 buys
Dhingra Ankur1 buy
Jacob Thaysen1 buy
+1 other insider
Since the insiders bought
- +26.7%Entry US$114.44 · Close at T+90 US$145.00
- +76.2%Entry US$80.90 · Close at T+365 US$142.54
- +76.2%Entry US$80.90 · Close at T+365 US$142.54
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Illumina, Inc. Buy (bullish), based on 20 analysts. Average price target: US$241.05.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,971 of 24,148 companies
57.9
score / 100
Value37
Quality79
FCF yld2.3%
Earn yld2.1%
EV/EBITDA29.0x
ROE32%
Gross mgn66%
Net mgn20%
Debt/EBITDA1.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$271.76
Analyst consensus
20 analystsBuy
US$113.00Target US$241.05(-11%)US$365.00
Income statement
RevenueUS$4.3B
Gross profitUS$2.9B66% margin
EBITDAUS$1.5B34% margin
Net incomeUS$850M18.3% margin
Valuation
PER (trailing)50.4x
PER (forward)44.4x
P/Book14.5x
Beta1.42
Balance sheet & cash
Market capUS$41B
Total debtUS$2.6B
Free Cash FlowUS$931M
Debt / Equity89%
Profitability & ownership
ROE32.3%
ROA8.7%
% insiders0.2%
% institutions106.4%
Last declaration on 7 October 2026
Declarations427 total
1,303 shares@ US$293.690.0009% mcap6.9% of flowCommon StockSEC:0001110803-26-000183:0
107 shares@ US$219.80370.0001% mcap0.0% of flowCommon StockSEC:0001110803-26-000181:0
113 shares@ US$219.80370.0001% mcap7.5% of flowCommon StockSEC:0001110803-26-000180:0
4,549 shares0Common StockSEC:0001110803-26-000177:0
14,214 shares0Common StockSEC:0001110803-26-000177:1
408 shares@ US$211.060.0002% mcap5.0% of flowCommon StockSEC:0001110803-26-000175:0
150,000 shares@ US$213.250.077% mcap7.3% of flowCommon Stock, par value $0.01 per shareSEC144:0001315863-26-000630
7,500 shares@ US$217.280.0039% mcap0.4% of flowCommon StockSEC:0001193125-26-383924:9
100,650 shares@ US$218.390.053% mcap4.8% of flowCommon StockSEC:0001193125-26-383924:10
14,196 shares@ US$217.290.0074% mcap0.7% of flowCommon StockSEC:0001193125-26-383924:4
9,961 shares@ US$221.550.0053% mcap0.5% of flowCommon StockSEC:0001193125-26-383924:8
57,488 shares@ US$213.200.030% mcap2.7% of flowCommon StockSEC:0001193125-26-383924:0
10,620 shares@ US$213.730.0055% mcap0.5% of flowCommon StockSEC:0001193125-26-383924:1
8,439 shares@ US$215.200.0044% mcap0.4% of flowCommon StockSEC:0001193125-26-383924:2
13,261 shares@ US$216.380.0069% mcap0.6% of flowCommon StockSEC:0001193125-26-383924:3
9,721 shares@ US$218.330.0051% mcap0.5% of flowCommon StockSEC:0001193125-26-383924:5
13,717 shares@ US$219.410.0072% mcap0.7% of flowCommon StockSEC:0001193125-26-383924:6
6,656 shares@ US$220.170.0035% mcap0.3% of flowCommon StockSEC:0001193125-26-383924:7
11,351 shares@ US$219.180.0060% mcap0.5% of flowCommon StockSEC:0001193125-26-383924:11
200,000 shares@ US$224.840.11% mcap10.3% of flowCommon Stock, par value $0.01 per shareSEC144:0001011438-26-000555
38,213 shares@ US$224.720.021% mcap1.8% of flowCommon StockSEC:0001193125-26-371756:3
4,873 shares@ US$226.740.0026% mcap0.2% of flowCommon StockSEC:0001193125-26-371756:7
16,990 shares@ US$229.720.0093% mcap0.8% of flowCommon StockSEC:0001193125-26-371756:10
92,776 shares@ US$225.260.050% mcap4.5% of flowCommon StockSEC:0001193125-26-371756:0
38,201 shares@ US$226.130.021% mcap1.9% of flowCommon StockSEC:0001193125-26-371756:1
25 of 427 declarations
About Illumina, Inc.
Illumina, Inc. is a leading genomics technology company listed on the Nasdaq (United States) under the ticker ILMN. Founded in 1998 in San Diego, California, the company built its franchise around DNA sequencing, microarray technologies, and related software and consumables. Its worldwide headquarters remain in San Diego, and its commercial footprint is global, with operations and customer support across the Americas, Europe, and Asia-Pacific. ([illumina.com](https://www.illumina.com/company/about-us.html?utm_source=openai))
Illumina’s business model is centered on selling sequencing platforms, reagents, consumables, analysis tools, and services to academic research institutions, pharmaceutical companies, biotech firms, hospitals, and molecular diagnostics players. The company is historically tied to sequencing-by-synthesis (SBS), a technology that became an industry standard, and it continues to invest in higher throughput, better accuracy, and lower cost per sample. That technology base has given Illumina a strong competitive position in high-throughput sequencing, although the market remains competitive, including from long-read sequencing specialists and other emerging platforms. ([illumina.com](https://www.illumina.com/content/dam/illumina-marketing/documents/company/illumina-corporate-fact-sheet-072214.pdf))
Read moreShow less
Illumina’s portfolio spans sequencing instruments, library-prep kits, chemistry, and interpretation software. Next-generation systems such as NovaSeq X and software products like DRAGEN are central to its strategy, alongside a growing focus on clinical genomics, precision oncology, translational research, and multiomics workflows. The company has also expanded its clinical oncology offering, including broader reimbursement for TSO Comprehensive after regulatory approval, which improves accessibility for clinicians and patients. ([investor.illumina.com](https://investor.illumina.com/news/press-release-details/2026/Illumina-unveils-roadmap-of-groundbreaking-NovaSeq-X-advancements-in-data-quality-output-speed-and-flexibility/default.aspx?utm_source=openai))
Geographically, Illumina is a U.S.-based company with a truly international revenue and operating profile. It serves customers in more than 160 countries and maintains offices and commercial teams across multiple regions. For French-speaking investors, this matters because it diversifies exposure beyond one market, while still leaving the company sensitive to laboratory capex cycles, public health budgets, and local regulatory developments. ([illumina.com](https://www.illumina.com/company/about-us.html?utm_source=openai))
Recent highlights underscore a renewed innovation push. Illumina reported full-year 2025 results on February 5, 2026, and first-quarter 2026 results on April 30, 2026, including Q1 revenue of $1.09 billion and a new $1.5 billion share repurchase authorization. In 2025 and 2026, the company also announced advances around oncology, 5-base solutions, DRAGEN v4.5, NovaSeq X improvements, and collaborations aimed at AI-enabled drug discovery. Taken together, these moves indicate a strategy focused on product innovation, operating leverage, and broader clinical adoption. ([investor.illumina.com](https://investor.illumina.com/news/press-release-details/2026/Illumina-Reports-Financial-Results-for-Fourth-Quarter-and-Fiscal-Year-2025/default.aspx))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
